{"id":"NCT02512510","sponsor":"Mylan Inc.","briefTitle":"Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09","primaryCompletion":"2016-08","completion":"2016-09","firstPosted":"2015-07-31","resultsPosted":"2018-12-31","lastUpdate":"2022-02-24"},"enrollment":611,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"TD-4208","otherNames":["revefenacin"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"TD-4208-1","type":"ACTIVE_COMPARATOR"},{"label":"TD-4208-2","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.","primaryOutcome":{"measure":"Change From Baseline in Trough FEV1 on Day 85","timeFrame":"Baseline and Day 85","effectByArm":[{"arm":"TD-4208-1","deltaMin":115.58,"sd":18.637},{"arm":"TD-4208-2","deltaMin":102.9,"sd":18.542},{"arm":"Placebo","deltaMin":-44.92,"sd":18.841}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["36681255","33124005","32393215"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":205},"commonTop":["Chronic obstructive pulmonary disease","Cough","Headache","Dyspnoea","Upper respiratory tract infection"]}}